KRAS and lung carcinoma: Similar compounds discovered by additional groups have led to the rapid development of direct KRAS G12C inhibitors, the most clinically advanced of which are MRTX849 (adagrasib) and AMG510 (sotorasib) [13–15], both of which are now FDA-approved for use in lung cancer.